Fig. 4: ERK5 pharmacological inhibition sensitizes colon cancer stem-like cells to 5-fluorouracil (5-FU)-based chemotherapy. | Cell Death Discovery

Fig. 4: ERK5 pharmacological inhibition sensitizes colon cancer stem-like cells to 5-fluorouracil (5-FU)-based chemotherapy.

From: MEK5/ERK5 activation regulates colon cancer stem-like cell properties

Fig. 4

HCT116 cells were grown for 7 days under sphere-forming conditions, and then treated for 4 days with FOLFOX (50 µM 5-FU plus 1.25 µM oxaliplatin) or FOLFIRI (50 µM 5-FU plus 1 µM irinotecan) alone or in combination with 4 µM XMD8-92. a Representative images of chemotherapy-treated tumorspheres at ×100 magnification. Scale bar, 100 μm. b Cell death was evaluated according to adenylate kinase (AK) release using the Toxilight assay. c Caspase-3/7 activity was measured using the Caspase-Glo 3/7 assay. d PARP cleavage and XIAP degradation were evaluated by western blot analysis. Results are expressed as mean ± standard error of mean from at least four independent experiments. p < 0.01 from vehicle control treatment; *p < 0.05, **p < 0.01, and ***p < 0.001 from FOLFOX/FOLFIRI-single treatment

Back to article page